Latest news

• Shire pitching at adult ADHD product launch in 2017

  Breaking into the adult ADHD - as well as a sideways move into binge-eating disorder with paediatric ADHD therapy Vyvanse (lisdexamfetamine) - could eventually double sales of Shire's psychiatric portfolio by

• Monica Seles to front Shire’s binge eating disorder campaign

  Shire recently won the first approval in the US for a medicine to help people with binge eating disorder with FDA backing for Vyvanse (lisdexamfetamine dimesylate).

• Shire gets FDA nod for first binge-eating treatment

  Vyvanse (lisdexamfetamine dimesylate) has been used to treat attention-deficit hyperactivity disorder (ADHD) for several years and remains Shire's top-selling product; sales rose 19% to reach more than $1bn

• AbbVie coaxes Shire into discussions with sweetened offer

  Shire has a well-established franchise in attention-deficit hyperactivity disorder (ADHD) drugs, currently headed by Vyvanse (lisdexamfetamine dimesylate), but has latterly built up a portfolio of rare disease therapies such

• Shire to file Vyvanse for binge-eating in Q3

  The company revealed yesterday that sales of Vyvanse (lisdexamfetamine) for ADHD rose 29 per cent in the fourth quarter to $330m, more than a quarter of Shire's total revenues of